MeiraGTx stock rises to EUR 8.78, volume 39.05 percent below average

Published on 10/15/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Its 52-week range was USD 6.62 to USD 15.35 on October 15, 2026. MeiraGTx stock costs EUR 8.78 on October 15, 2026, up 4.36 percent on Nasdaq.

Trading range and valuation

MeiraGTx recorded a 4.36 percent Nasdaq gain on October 15, 2026.
Trading volume reached 472,247 shares, 39.05 percent below the average.
MeiraGTx stock costs EUR 8.78 at Lang & Schwarz on October 15, 2026 at 9:18 p.m. CEST, up 4.36 percent on Nasdaq.
MarketBeat cited a USD 24.71 average target from nine analysts on October 2, 2026.

MGTX, KYG596651029, Illustration mit AI erstellt.

MeiraGTx stock rose 4.36 percent on Nasdaq on October 15, 2026, while volume remained below its recent average. MarketWatch identifies the company as a Nasdaq listing. At Lang & Schwarz, the stock was trading at EUR 8.78 on October 15, 2026 at 9:18 p.m. CEST, up 4.36 percent on Nasdaq.

Range and trading activity

The 52-week range stands at USD 6.62 to USD 15.35 as of October 15, 2026. The current price therefore remains inside a wide trading corridor for the clinical-stage biotechnology company.

Volume reached 472,247 shares on October 15, 2026, compared with an average of 774,837 shares. That places turnover 39.05 percent below the average, giving the daily advance less volume support than a typical session.

Valuation and analyst view

MeiraGTx had a market capitalization of USD 943.1 million and a price-to-earnings ratio of 13.83 on October 15, 2026. The company paid no dividend yield in the quoted period.

MarketBeat reported on October 2, 2026, that nine analysts gave MeiraGTx a Moderate Buy consensus and an average 12-month target of USD 24.71. The same report cited Goldman Sachs with a Neutral rating and a USD 16.00 target from September 24, 2026. The target range highlights the gap between the current quotation and analysts' published assumptions, rather than providing a forecast from this desk.

Company and pipeline

MeiraGTx describes itself as a vertically integrated genetic medicines company with late-stage programs in Parkinson's disease, radiation-induced dry mouth and inherited retinal disease. Its platform combines targeted delivery, viral-vector manufacturing and gene regulation technology.

Comparison with peers

MeiraGTx (Nasdaq, USD): plus 4.36 percent, P/E 13.83, market capitalization USD 943.1 million
CRISPR Therapeutics (Nasdaq, USD): plus 3.62 percent, P/E minus 10.93, market capitalization USD 5.0 billion
Editas Medicine (Nasdaq, USD): plus 7.05 percent, P/E minus 3.25, market capitalization USD 373.2 million

Closing price context

The price move places MeiraGTx among the stronger daily performers in this selected gene-therapy comparison, although its market value remains below CRISPR Therapeutics and above Editas Medicine. The further course of trading is shown by the continuously updated real-time quote of MeiraGTx stock.